Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Escherichia coli Infections - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Escherichia coli Infections - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Escherichia coli Infections - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Escherichia coli Infections - Pipeline Review, H1 2018



Executive Summary

Escherichia coli Infections - Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2018, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

 

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4, 1, 37 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 14 molecules, respectively.

 

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Escherichia coli Infections - Overview 6

Escherichia coli Infections - Therapeutics Development 7

Escherichia coli Infections - Therapeutics Assessment 18

Escherichia coli Infections - Companies Involved in Therapeutics Development 27

Escherichia coli Infections - Drug Profiles 42

Escherichia coli Infections - Dormant Projects 165

Escherichia coli Infections - Discontinued Products 169

Escherichia coli Infections - Product Development Milestones 170

Appendix 181

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Escherichia coli Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Escherichia coli Infections - Pipeline by ABAC Therapeutics SA, H1 2018

Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1 2018

Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1 2018

Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2018

Escherichia coli Infections - Pipeline by ContraFect Corp, H1 2018

Escherichia coli Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Escherichia coli Infections - Pipeline by Debiopharm International SA, H1 2018

Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H1 2018

Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H1 2018

Escherichia coli Infections - Pipeline by Immuron Ltd, H1 2018

Escherichia coli Infections - Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Escherichia coli Infections - Pipeline by Johnson & Johnson, H1 2018

Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Escherichia coli Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H1 2018

Escherichia coli Infections - Pipeline by Merck & Co Inc, H1 2018

Escherichia coli Infections - Pipeline by Microbiotix Inc, H1 2018

Escherichia coli Infections - Pipeline by Nabriva Therapeutics plc, H1 2018

Escherichia coli Infections - Pipeline by Navigen Inc, H1 2018

Escherichia coli Infections - Pipeline by Northern Antibiotics Oy, H1 2018

Escherichia coli Infections - Pipeline by Nosopharm SAS, H1 2018

Escherichia coli Infections - Pipeline by Novabiotics Ltd, H1 2018

Escherichia coli Infections - Pipeline by Oxford Drug Design Ltd, H1 2018

Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H1 2018

Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H1 2018

Escherichia coli Infections - Pipeline by Protein Potential LLC, H1 2018

Escherichia coli Infections - Pipeline by PTC Therapeutics Inc, H1 2018

Escherichia coli Infections - Pipeline by Recce Ltd, H1 2018

Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2018

Escherichia coli Infections - Pipeline by Syntiron LLC, H1 2018

Escherichia coli Infections - Pipeline by TCM Biotech International Corp, H1 2018

Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018

Escherichia coli Infections - Pipeline by Venus Medicine Research Center, H1 2018

Escherichia coli Infections - Dormant Projects, H1 2018

Escherichia coli Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018

Escherichia coli Infections - Dormant Projects, H1 2018 (Contd..2), H1 2018

Escherichia coli Infections - Dormant Projects, H1 2018 (Contd..3), H1 2018

Escherichia coli Infections - Discontinued Products, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ABAC Therapeutics SA

Adenium Biotech ApS

AstraZeneca Plc

Atterx Biotherapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

Hsiri Therapeutics LLC

Immuron Ltd

Innovation Pharmaceuticals Inc

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Nabriva Therapeutics plc

Navigen Inc

Northern Antibiotics Oy

Nosopharm SAS

Novabiotics Ltd

Oxford Drug Design Ltd

Paratek Pharmaceuticals Inc

Phico Therapeutics Ltd

Protein Potential LLC

PTC Therapeutics Inc

Recce Ltd

Sealife PHARMA GMBH

Syntiron LLC

TCM Biotech International Corp

Tetraphase Pharmaceuticals Inc

Venus Medicine Research Center

Escherichia coli Infections Therapeutic Products under Development, Key Players in Escherichia coli Infections Therapeutics, Escherichia coli Infections Pipeline Overview, Escherichia coli Infections Pipeline, Escherichia coli Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand